On ECHEMI
Home > Drugs > Ovarian cancer
Ovarian cancer
Ovarian cancer is one of the common tumors of female reproductive organs, and its incidence rate ranks third after cervical cancer and uterine body cancer. However, deaths caused by ovarian cancer account for the first place among all kinds of gynecological tumors, posing a serious threat to women's lives. Due to the complex embryonic development, tissue anatomy and endocrine function of the ovaries, the tumors it suffers from may be benign or malignant. Since ovarian cancer has no symptoms in the early clinical stage, it is quite difficult to distinguish its tissue type and benign or malignant. During laparotomy for ovarian cancer, only 30% of the tumors are found to be confined to the ovaries, and most of them have spread to the uterus, bilateral adnexa, greater omentum and pelvic organs. Therefore, ovarian cancer is indeed a big problem in both diagnosis and treatment. Over the years, experts have conducted many discussions on the pathological morphology, clinical occurrence and development rules and treatment plans of ovarian malignant tumors, and accumulated a lot of experience. So far, according to clinical data statistics at home and abroad, its five-year survival rate is only 25% to 30%.
Related Drugs
Hexamethylmelamine
Indication: It is mainly used to treat ovarian cancer, and can also be used to treat bronchial lung cancer, breast cancer and malignant lymphoma.
Hexamethylmelamine
Indication: It is mainly used to treat ovarian cancer, and can also be used to treat bronchial lung cancer, breast cancer and malignant lymphoma.
Hexamethylmelamine capsules
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Manufacturer:

ZHONGFU Pharmaceutical Co., Ltd.

Hexamethylmelamine capsules
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Manufacturer:

Yunnan Phyto Pharmaceutical Co., Ltd.

Hexamethylmelamine tablets
Indication: This product is used for combined chemotherapy of ovarian cancer, SCLC, malignant lymphoma, and endometrial cancer, and is particularly effective for ovarian cancer and SCLC.
Vinorelbine tartrate
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:

Qilu Pharmaceutical (Hainan) Co., Ltd.

Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Cisen Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.